Lv7
5000 积分 2024-01-08 加入
A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus
1天前
已完结
Non-Hodgkin lymphoma
4天前
已完结
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026
8天前
已完结
Safety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic Leukemia
8天前
已完结
Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)
22天前
已关闭
Beyond MURANO: sequencing therapy in relapsed chronic lymphocytic leukaemia
26天前
已完结
Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia
1个月前
已完结
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
1个月前
已完结
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
1个月前
已完结
皖公网安备34019202002308
